688428 诺诚健华
已收盘 12-16 15:00:00
资讯
新帖
简况
12月16日诺诚健华跌6.09%，富国精准医疗混合A基金重仓该股
证券之星 · 12-16 15:36
12月16日诺诚健华跌6.09%，富国精准医疗混合A基金重仓该股
创新药概念再度走低 诺诚健华(09969.HK)跌超5%
每日经济新闻 · 12-16 11:21
创新药概念再度走低 诺诚健华(09969.HK)跌超5%
诺诚健华：截至2025年11月28日A股股东户数约1.79万户
证券日报 · 12-15 21:43
诺诚健华：截至2025年11月28日A股股东户数约1.79万户
诺诚健华宣布Orelabrutinib在SLE的二期临床试验中达到主要终点，并获批三期临床试验
美股速递 · 12-14 17:50
诺诚健华宣布Orelabrutinib在SLE的二期临床试验中达到主要终点，并获批三期临床试验
诺诚健华(688428.SH)：奥布替尼治疗系统性红斑狼疮IIb期研究达到主要终点
智通财经 · 12-14 16:27
诺诚健华(688428.SH)：奥布替尼治疗系统性红斑狼疮IIb期研究达到主要终点
港股诺诚健华涨超3%
每日经济新闻 · 12-12
港股诺诚健华涨超3%
港股异动 | 诺诚健华(09969)涨超3% 预计不久将递交佐来曲替尼治疗儿童患者新药上市申请
智通财经网 · 12-12
港股异动 | 诺诚健华(09969)涨超3% 预计不久将递交佐来曲替尼治疗儿童患者新药上市申请
诺诚健华宣布宜诺凯（奥布替尼）新增适应症纳入2025年国家医保药品目录
证券日报 · 12-07
诺诚健华宣布宜诺凯（奥布替尼）新增适应症纳入2025年国家医保药品目录
诺诚健华（688428）披露证券变动月报表，12月04日股价上涨1.89%
证券之星 · 12-04
诺诚健华（688428）披露证券变动月报表，12月04日股价上涨1.89%
诺诚健华宣布新型TYK2抑制剂Soficitinib治疗结节性痒疹的全球II期临床试验完成首例患者给药
证券日报 · 11-29
诺诚健华宣布新型TYK2抑制剂Soficitinib治疗结节性痒疹的全球II期临床试验完成首例患者给药
诺诚健华：截至目前，公司暂无自研药品于欧盟范围内获批及销售
每日经济新闻 · 11-28
诺诚健华：截至目前，公司暂无自研药品于欧盟范围内获批及销售
诺诚健华宣布全球II期临床试验首例患者接受Tyk2抑制剂索菲替尼治疗结节性瘙痒症
美股速递 · 11-28
诺诚健华宣布全球II期临床试验首例患者接受Tyk2抑制剂索菲替尼治疗结节性瘙痒症
每周股票复盘：诺诚健华（688428）奥布替尼2025年1-9月销售收入达10.10亿元
证券之星 · 11-23
每周股票复盘：诺诚健华（688428）奥布替尼2025年1-9月销售收入达10.10亿元
每周股票复盘：诺诚健华（688428）Q3营收增38.09%
证券之星 · 11-16
每周股票复盘：诺诚健华（688428）Q3营收增38.09%
图解诺诚健华三季报：第三季度单季净利润同比下降152.94%
证券之星 · 11-13
图解诺诚健华三季报：第三季度单季净利润同比下降152.94%
诺诚健华(688428.SH)发布前三季度业绩，归母净亏损6441万元
智通财经 · 11-13
诺诚健华(688428.SH)发布前三季度业绩，归母净亏损6441万元
每周股票复盘：诺诚健华（688428）购回80万股份
证券之星 · 11-09
每周股票复盘：诺诚健华（688428）购回80万股份
诺诚健华（688428）披露证券变动月报表，11月05日股价下跌1.49%
证券之星 · 11-05
诺诚健华（688428）披露证券变动月报表，11月05日股价下跌1.49%
每周股票复盘：诺诚健华（688428）将发布Q3业绩
证券之星 · 11-02
每周股票复盘：诺诚健华（688428）将发布Q3业绩
每周股票复盘：诺诚健华（688428）获1亿美元首付款及700万股市值合作
证券之星 · 10-19
每周股票复盘：诺诚健华（688428）获1亿美元首付款及700万股市值合作
公司概况
公司名称：
诺诚健华医药有限公司
所属行业：
医药制造业
上市日期：
2022-09-21
主营业务：
诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼、坦昔妥单抗、ICP-248、ICP-B02。公司2023年被认定为国家级专精特新“小巨人”企业。
发行价格：
11.03
{"stockData":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":22.5,"timestamp":1765868400000,"preClose":23.96,"halted":0,"volume":7546477,"delay":0,"changeRate":-0.0609,"floatShares":268000000,"shares":1764999999,"eps":-0.1302,"marketStatus":"已收盘","change":-1.46,"latestTime":"12-16 15:00:00","open":23.78,"high":24.11,"low":22.45,"amount":172000000,"amplitude":0.0693,"askPrice":22.51,"askSize":17,"bidPrice":22.5,"bidSize":72,"shortable":0,"etf":0,"ttmEps":-0.1302,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765935000000},"marketStatusCode":5,"adr":0,"adjPreClose":23.96,"symbolType":"stock_kcb","openAndCloseTimeList":[[1765848600000,1765855800000],[1765861200000,1765868400000]],"highLimit":26.36,"lowLimit":21.56,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1764643952,"isCdr":false,"pbRate":5.96,"roa":"--","roe":"--","epsLYR":-0.26,"committee":0.519841,"marketValue":39704000000,"turnoverRate":0.0281,"status":1,"afterMarket":{"amount":0,"volume":0,"close":22.5,"buyVolume":0,"sellVolume":0,"time":1765870437768,"indexStatus":"已收盘 12-16 15:30:00","preClose":23.96},"hkstockBrief":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":13.28,"timestamp":1765872500011,"preClose":13.55,"halted":0,"volume":7215000,"delay":0,"premium":"-46.64"},"floatMarketCap":6038000000},"requestUrl":"/m/hq/s/688428/wiki","defaultTab":"wiki","newsList":[{"id":"2591097566","title":"12月16日诺诚健华跌6.09%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591097566","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591097566?lang=zh_cn&edition=full","pubTime":"2025-12-16 15:36","pubTimestamp":1765870568,"startTime":"0","endTime":"0","summary":"证券之星消息，12月16日诺诚健华跌6.09%，收盘报22.5元，换手率2.81%，成交量7.55万手，成交额1.72亿元。重仓诺诚健华的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共30家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为34.91亿元，最新净值3.1742，较上一交易日下跌3.71%，近一年上涨34.53%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600020122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","BK1574","BK1161","BK0239","09969"],"gpt_icon":0},{"id":"2591565672","title":"创新药概念再度走低 诺诚健华(09969.HK)跌超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591565672","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591565672?lang=zh_cn&edition=full","pubTime":"2025-12-16 11:21","pubTimestamp":1765855266,"startTime":"0","endTime":"0","summary":"每经AI快讯，创新药概念股再度走低，截至发稿，诺诚健华(09969.HK)跌5.09%，报12.86港元；石药集团(01093.HK)跌3.99%，报7.21港元；信达生物(01801.HK)跌3.36%，报79港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512163592831521.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512163592831521.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1161","BK0239","688428","159992","09969","06978"],"gpt_icon":0},{"id":"2591644571","title":"诺诚健华：截至2025年11月28日A股股东户数约1.79万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2591644571","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591644571?lang=zh_cn&edition=full","pubTime":"2025-12-15 21:43","pubTimestamp":1765806180,"startTime":"0","endTime":"0","summary":"证券日报网讯12月15日，诺诚健华在互动平台回答投资者提问时表示，截至2025年11月28日公司A股股东户数约为1.79万户。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512153592007823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","159982","BK1161","BK1574","688428","09969","399300"],"gpt_icon":0},{"id":"1121316255","title":"诺诚健华宣布Orelabrutinib在SLE的二期临床试验中达到主要终点，并获批三期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1121316255","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121316255?lang=zh_cn&edition=full","pubTime":"2025-12-14 17:50","pubTimestamp":1765705817,"startTime":"0","endTime":"0","summary":"诺诚健华宣布Orelabrutinib在SLE的二期临床试验中达到主要终点，并获批三期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688428"],"gpt_icon":0},{"id":"2591665068","title":"诺诚健华(688428.SH)：奥布替尼治疗系统性红斑狼疮IIb期研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2591665068","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591665068?lang=zh_cn&edition=full","pubTime":"2025-12-14 16:27","pubTimestamp":1765700828,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(688428.SH)公告，公司自主研发的BTK抑制剂奥布替尼治疗系统性红斑狼疮(简称“SLE”)的IIb期临床研究达到主要终点，并获国家药品监督管理局(NMPA)药品审评中心(CDE)批准开展III期注册性临床试验。公司将尽快启动该临床研究。临床IIb结果展示，在接受治疗48周的患者中，奥布替尼展现了卓越的有效性、良好的耐受性和安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688428","BK0239","BK1574","09969","BK1161"],"gpt_icon":0},{"id":"2590257886","title":"港股诺诚健华涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590257886","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590257886?lang=zh_cn&edition=full","pubTime":"2025-12-12 14:21","pubTimestamp":1765520510,"startTime":"0","endTime":"0","summary":"每经AI快讯，诺诚健华(09969.HK)涨超3%，截至发稿，涨3.24%，报14港元，成交额5105.45万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512123590068918.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512123590068918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","09969","BK0239","BK1161","688428"],"gpt_icon":0},{"id":"2590520907","title":"港股异动 | 诺诚健华(09969)涨超3% 预计不久将递交佐来曲替尼治疗儿童患者新药上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2590520907","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590520907?lang=zh_cn&edition=full","pubTime":"2025-12-12 14:05","pubTimestamp":1765519550,"startTime":"0","endTime":"0","summary":"消息面上，12月11日，诺诚健发布公告，国家药品监督管理局已批准第二代小分子泛原肌球蛋白相关激酶抑制剂佐来曲替尼，用于治疗携带NTRK融合基因的成人和12岁以上青少年实体瘤患者。佐来曲替尼已被NMPA纳入“星光计划”，该计划是一项为鼓励儿童抗肿瘤药物研发而开展的试点项目。本公司预计不久将递交佐来曲替尼治疗儿童患者的新药上市申请。NTRK融合基因存在于各种类型的肿瘤，目前已在超过26种实体瘤中发现了NTRK融合基因。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380803.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","688428","09969","BK0239","BK1161"],"gpt_icon":0},{"id":"2589712808","title":"诺诚健华宣布宜诺凯（奥布替尼）新增适应症纳入2025年国家医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589712808","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589712808?lang=zh_cn&edition=full","pubTime":"2025-12-07 18:07","pubTimestamp":1765102044,"startTime":"0","endTime":"0","summary":"12月7日，2025年《国家基本医疗保险、生育保险和工伤保险药品目录》（国家医保药品目录）在广州正式公布。诺诚健华医药有限公司（以下简称“诺诚健华”）自主研发的布鲁顿酪氨酸激酶（BTK）抑制剂宜诺凯?（奥布替尼）新增适应症被纳入2025年国家医保药品目录，用于一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512073584604256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK0239","BK1161","688428","09969"],"gpt_icon":0},{"id":"2588880472","title":"诺诚健华（688428）披露证券变动月报表，12月04日股价上涨1.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588880472","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588880472?lang=zh_cn&edition=full","pubTime":"2025-12-04 22:20","pubTimestamp":1764858034,"startTime":"0","endTime":"0","summary":"截至2025年12月4日收盘，诺诚健华报收于24.84元，较前一交易日上涨1.89%，最新总市值为438.34亿元。公司近日发布公告，披露截至2025年11月30日的证券变动月报表。公告显示，诺诚健华医药有限公司法定股本无变动，已发行股份总数保持不变。公司存在股权激励计划，包括2023年及2024年人民币股股份激励计划，部分限制性股票已失效，但本月未发生新股发行或库存股转让。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400039635.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688428","BK1574","161027","09969","BK0239"],"gpt_icon":0},{"id":"2587751162","title":"诺诚健华宣布新型TYK2抑制剂Soficitinib治疗结节性痒疹的全球II期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2587751162","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2587751162?lang=zh_cn&edition=full","pubTime":"2025-11-29 11:36","pubTimestamp":1764387398,"startTime":"0","endTime":"0","summary":"11月28日，诺诚健华医药有限公司（以下简称“诺诚健华”）宣布，公司自主研发的新型TYK2抑制剂Soficitinib（ICP-332）治疗结节性痒疹的全球II期临床试验完成首例患者给药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511293578279828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","688428","BK0239","BK1161","09969"],"gpt_icon":1},{"id":"2586189785","title":"诺诚健华：截至目前，公司暂无自研药品于欧盟范围内获批及销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2586189785","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586189785?lang=zh_cn&edition=full","pubTime":"2025-11-28 18:15","pubTimestamp":1764324916,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：请问贵公司近两年是否出口欧盟国家？诺诚健华（688428.SH）11月28日在投资者互动平台表示，尊敬的投资者，您好！截至目前，公司暂无自研药品于欧盟范围内获批及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511283577874557.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511283577874557.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK1574","09969","688428","BK1161"],"gpt_icon":0},{"id":"1169461698","title":"诺诚健华宣布全球II期临床试验首例患者接受Tyk2抑制剂索菲替尼治疗结节性瘙痒症","url":"https://stock-news.laohu8.com/highlight/detail?id=1169461698","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169461698?lang=zh_cn&edition=full","pubTime":"2025-11-28 09:56","pubTimestamp":1764295015,"startTime":"0","endTime":"0","summary":"诺诚健华宣布全球II期临床试验首例患者接受Tyk2抑制剂索菲替尼治疗结节性瘙痒症","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","BK0239"],"gpt_icon":0},{"id":"2585103116","title":"每周股票复盘：诺诚健华（688428）奥布替尼2025年1-9月销售收入达10.10亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2585103116","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585103116?lang=zh_cn&edition=full","pubTime":"2025-11-23 02:43","pubTimestamp":1763836991,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，诺诚健华报收于23.36元，较上周的25.34元下跌7.81%。本周，诺诚健华11月17日盘中最高价报25.42元。本周关注点来自业绩披露要点：奥布替尼2025年1-9月销售收入达10.10亿元，同比增长45.77%。来自机构调研要点：奥布替尼全球Ⅲ期试验将与Zenas分别于2025年底及2026年Q1启动。答：公司2025年1-9月总营业收入11.15亿元，同比增长59.85%，毛利率88.8%。公司已在2025年第四季度收到Zenas支付的现金首付款及500万股普通股，带来即期财务收益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000627.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK1574","BK1161","688428","BK0239"],"gpt_icon":0},{"id":"2583594586","title":"每周股票复盘：诺诚健华（688428）Q3营收增38.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583594586","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583594586?lang=zh_cn&edition=full","pubTime":"2025-11-16 02:33","pubTimestamp":1763231592,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，诺诚健华报收于25.34元，较上周的23.86元上涨6.2%。本周，诺诚健华11月13日盘中最高价报25.95元。本周关注点业绩披露要点：诺诚健华2025年第三季度营收3.84亿元，同比增长38.09%。公司公告汇总诺诚健华医药有限公司2025年第三季度报告显示，本报告期营业收入383,894,221.54元，同比增长38.09%；年初至报告期末营业收入1,115,328,393.86元，同比增长59.85%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","09969"],"gpt_icon":0},{"id":"2583569524","title":"图解诺诚健华三季报：第三季度单季净利润同比下降152.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583569524","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583569524?lang=zh_cn&edition=full","pubTime":"2025-11-13 19:02","pubTimestamp":1763031737,"startTime":"0","endTime":"0","summary":"证券之星消息，诺诚健华2025年三季报显示，前三季度公司主营收入11.15亿元，同比上升59.85%；归母净利润-6441.49万元，同比上升76.61%；扣非净利润-1.35亿元，同比上升49.32%；其中2025年第三季度，公司单季度主营收入3.84亿元，同比上升38.09%；单季度归母净利润-3432.35万元，同比下降152.94%；单季度扣非净利润-5307.75万元，同比下降265.85%；负债率29.88%，投资收益3652.65万元，财务费用-7494.74万元，毛利率88.78%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300034903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","09969"],"gpt_icon":0},{"id":"2583155085","title":"诺诚健华(688428.SH)发布前三季度业绩，归母净亏损6441万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583155085","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583155085?lang=zh_cn&edition=full","pubTime":"2025-11-13 17:11","pubTimestamp":1763025111,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(688428.SH)披露2025年第三季度报告，公司前三季度实现营收11.15亿元，同比增长59.85%;归属于上市公司股东的净利润亏损6441万元;扣非净利润亏损1.35亿元;基本每股收益-0.04元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368837.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688428","BK0239","BK1574","09969","BK1161"],"gpt_icon":0},{"id":"2582864806","title":"每周股票复盘：诺诚健华（688428）购回80万股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2582864806","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582864806?lang=zh_cn&edition=full","pubTime":"2025-11-09 04:40","pubTimestamp":1762634416,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，诺诚健华报收于23.86元，较上周的24.53元下跌2.73%。本周，诺诚健华11月3日盘中最高价报24.79元。诺诚健华当前最新总市值421.04亿元，在化学制药板块市值排名12/151，在两市A股市值排名430/5166。本周关注点公司公告汇总：诺诚健华于2025年10月10日购回800,000股股份作为库存股，价格为每股14.71港元。公司公告汇总诺诚健华医药有限公司截至2025年10月31日的证券变动月报表显示，公司法定/注册股本无变动，总额为50,000美元，每股面值0.000002美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001674.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","BK1161","BK0239","BK1574","09969"],"gpt_icon":0},{"id":"2581895776","title":"诺诚健华（688428）披露证券变动月报表，11月05日股价下跌1.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581895776","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581895776?lang=zh_cn&edition=full","pubTime":"2025-11-05 22:28","pubTimestamp":1762352904,"startTime":"0","endTime":"0","summary":"截至2025年11月5日收盘，诺诚健华报收于23.88元，较前一交易日下跌1.49%，最新总市值为421.4亿元。公司近日发布公告，披露截至2025年10月31日的证券变动月报表。公告显示，诺诚健华法定/注册股本无变动，总额为50,000美元，每股面值0.000002美元。根据2023年及2024年人民币股股份激励计划，部分限制性股票失效，截至2025年10月末，累计4,531,250股及9,702,200股可能发行。2025年10月10日，公司购回800,000股股份作为库存股，价格为每股14.71港元，股东大会通过日期为2025年6月20日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500040774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","161027","BK1574","688428","BK1161","09969"],"gpt_icon":0},{"id":"2580947560","title":"每周股票复盘：诺诚健华（688428）将发布Q3业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2580947560","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580947560?lang=zh_cn&edition=full","pubTime":"2025-11-02 02:57","pubTimestamp":1762023430,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，诺诚健华报收于24.53元，较上周的22.41元上涨9.46%。本周，诺诚健华10月31日盘中最高价报24.72元。诺诚健华当前最新总市值432.87亿元，在化学制药板块市值排名12/151，在两市A股市值排名411/5163。本周关注点公司公告汇总：诺诚健华将于2025年11月13日召开董事会，审议并发布截至2025年9月30日止九个月的未经审核第三季度业绩。承董事会命，诺诚健华医药有限公司，香港，2025年10月31日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","BK1161","688428","09969"],"gpt_icon":0},{"id":"2576464700","title":"每周股票复盘：诺诚健华（688428）获1亿美元首付款及700万股市值合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2576464700","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576464700?lang=zh_cn&edition=full","pubTime":"2025-10-19 03:06","pubTimestamp":1760814371,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，诺诚健华报收于23.75元，较上周的24.29元下跌2.22%。本周，诺诚健华10月14日盘中最高价报25.62元。本周关注点来自机构调研要点：诺诚健华与Zenas达成超20亿美元合作，获1亿美元首付款及700万普通股。交易已生效，公司收到首笔现金首付款，并获发500万股Zenas普通股，带来即期财务收益并增强现金储备。公司公告汇总诺诚健华于2025年10月10日购回800,000股普通股，每股价格14.71港元，总金额11,768,000港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101900000581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK1161","688428","BK0239","BK1574"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765901078883,"stockEarnings":[{"period":"1week","weight":-0.0439},{"period":"1month","weight":-0.0545},{"period":"3month","weight":-0.1227},{"period":"6month","weight":-0.0389},{"period":"1year","weight":0.7579},{"period":"ytd","weight":0.9511}],"compareEarnings":[{"period":"1week","weight":-0.0143},{"period":"1month","weight":-0.0307},{"period":"3month","weight":0.0016},{"period":"6month","weight":0.1414},{"period":"1year","weight":0.1403},{"period":"ytd","weight":0.154}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"诺诚健华医药有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"17900人(较上一季度减少4.79%)","perCapita":"14992股","listingDate":"2022-09-21","address":"Ogier Global(Cayman)Limited 89 Nexus Way Camana Bay Grand Cayma KY1-9009 Cayman Islands","registeredCapital":"0万元","survey":" 诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼、坦昔妥单抗、ICP-248、ICP-B02。公司2023年被认定为国家级专精特新“小巨人”企业。","listedPrice":11.03},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,688428,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}